275 related articles for article (PubMed ID: 18628452)
1. Targeted therapies to improve tumor immunotherapy.
Begley J; Ribas A
Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
[TBL] [Abstract][Full Text] [Related]
2. Combining cancer immunotherapy and targeted therapy.
Ribas A; Wolchok JD
Curr Opin Immunol; 2013 Apr; 25(2):291-6. PubMed ID: 23561594
[TBL] [Abstract][Full Text] [Related]
3. CD8
Chen Y; Yu D; Qian H; Shi Y; Tao Z
J Transl Med; 2024 Apr; 22(1):394. PubMed ID: 38685033
[TBL] [Abstract][Full Text] [Related]
4. Small Particles, Big Effects: The Interplay Between Exosomes and Dendritic Cells in Antitumor Immunity and Immunotherapy.
Benites BD; Alvarez MC; Saad STO
Cells; 2019 Dec; 8(12):. PubMed ID: 31888159
[TBL] [Abstract][Full Text] [Related]
5. "Tumor immunology meets oncology (TIMO) XII", April 28th-30th 2016, Halle/Saale, Germany.
Seliger B
Cancer Immunol Immunother; 2017 Nov; 66(11):1497-1503. PubMed ID: 28695228
[No Abstract] [Full Text] [Related]
6. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
7. Immune escape mechanisms as a guide for cancer immunotherapy.
Beatty GL; Gladney WL
Clin Cancer Res; 2015 Feb; 21(4):687-92. PubMed ID: 25501578
[TBL] [Abstract][Full Text] [Related]
8. Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3-5, 2011.
Aptsiauri N; Cabrera T; Garcia-Lora A; Garrido F
Cancer Immunol Immunother; 2012 May; 61(5):739-45. PubMed ID: 22350069
[No Abstract] [Full Text] [Related]
9. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.
Wang DR; Wu XL; Sun YL
Signal Transduct Target Ther; 2022 Sep; 7(1):331. PubMed ID: 36123348
[TBL] [Abstract][Full Text] [Related]
10. RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies.
Pollack R; Stokar J; Lishinsky N; Gurt I; Kaisar-Iluz N; Shaul ME; Fridlender ZG; Dresner-Pollak R
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445704
[TBL] [Abstract][Full Text] [Related]
11. AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation.
Caforio M; Tumino N; Sorino C; Manni I; Di Giovenale S; Piaggio G; Iezzi S; Strimpakos G; Mattei E; Moretta L; Fanciulli M; Vacca P; Locatelli F; Folgiero V
Front Immunol; 2023; 14():1191908. PubMed ID: 37435061
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
Jiang Y; Hong K; Zhao Y; Xu K
Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
[TBL] [Abstract][Full Text] [Related]
13. Complement system in Anti-CD20 mAb therapy for cancer: A mini-review.
Gao Y
Int J Immunopathol Pharmacol; 2023; 37():3946320231181464. PubMed ID: 37357623
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
Yu WD; Sun G; Li J; Xu J; Wang X
Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy augments oxaliplatin-induced immunogenic cell death in colorectal cancer.
Wang X; Ren L; Ye L; Cao J
Cent Eur J Immunol; 2023; 48(3):189-202. PubMed ID: 37901869
[TBL] [Abstract][Full Text] [Related]
16. Advances in targeted therapy and immunotherapy for melanoma (Review).
Qin Z; Zheng M
Exp Ther Med; 2023 Sep; 26(3):416. PubMed ID: 37559935
[TBL] [Abstract][Full Text] [Related]
17. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.
Meza L; Zengin Z; Salgia S; Malhotra J; Karczewska E; Dorff T; Tripathi A; Ely J; Kelley E; Mead H; Hsu J; Dizman N; Salgia N; Chawla N; Chehrazi-Raffle A; Muddasani R; Govindarajan A; Rock A; Liu S; Salgia R; Trent J; Altin J; Pal SK
Oncologist; 2023 Sep; 28(9):e748-e755. PubMed ID: 36971500
[TBL] [Abstract][Full Text] [Related]
18. Combined targeted therapy and immunotherapy for cancer treatment.
Guo CX; Huang X; Xu J; Zhang XZ; Shen YN; Liang TB; Bai XL
World J Clin Cases; 2021 Sep; 9(26):7643-7652. PubMed ID: 34621816
[TBL] [Abstract][Full Text] [Related]
19. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in
Ferrucci PF; Di Giacomo AM; Del Vecchio M; Atkinson V; Schmidt H; Schachter J; Queirolo P; Long GV; Stephens R; Svane IM; Lotem M; Abu-Amna M; Gasal E; Ghori R; Diede SJ; Croydon ES; Ribas A; Ascierto PA;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361337
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
